Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Myelofibrosis · Acute Myeloid Leukemia

Karyopharm Therapeutics

Karyopharm Therapeutics Inc

Karyopharm Therapeutics patent portfolio — 38 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
85 Wells Avenue, Newton, MA 02459, US HQ
313 Employees
NMPA registrant Type
Company details
Status
Public
HQ
85 Wells Avenue, Newton, MA 02459, US
Employees
313
Programs
82
Drugs
53
Patents
38
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

Karyopharm Therapeutics patents

38 pharmaceutical patents indexed for Karyopharm Therapeutics. 0 expire within 24 months.

Karyopharm Therapeutics has 38 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

38 patents

Patent portfolio

  1. US 12371420

    Polymorphs of Selinexor

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12331040

    Substituted benzofuranyl and benzoxazolyl compounds and uses thereof

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12318386

    Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12291508

    Hydrazide containing nuclear transport modulators and uses thereof

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11945794

    Nuclear transport modulators and uses thereof

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11807629

    Polymorphs of Selinexor

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11787771

    Hydrazide containing nuclear transport modulators and uses thereof

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11753401

    Polymorphs of Selinexor

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11746102

    Polymorphs of selinexor

    Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11124493

    Nuclear transport modulators and uses thereof

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11078190

    Polymorphs of selinexor

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11034660

    Hydrazide containing nuclear transport modulators and uses thereof

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11008309

    Substituted benzofuranyl and benzoxazolyl compounds and uses thereof

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10858347

    Multicyclic compounds and uses thereof

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10544108

    Hydrazide containing nuclear transport modulators and uses thereof

    Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10526295

    Nuclear transport modulators and uses thereof

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10519139

    Polymorphs of Selinexor

    Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10407405

    Nuclear transport modulators and uses thereof

    Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10399963

    Substituted benzofuranyl and benzoxazolyl compounds and uses thereof

    Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10363247

    (S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10202366

    Methods of promoting wound healing using CRM1 inhibitors

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10173987

    Hydrazide containing nuclear transport modulators and uses thereof

    Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9994558

    Multicyclic compounds and methods of using same

    Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9938258

    Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9861614

    Nuclear transport modulators and uses thereof

    Expires Mon Jan 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9856241

    Substituted benzofuranyl and benzoxazolyl compounds and uses thereof

    Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9738624

    Nuclear transport modulators and uses thereof

    Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9714226

    Hydrazide containing nuclear transport modulators and uses thereof

    Expires Mon Jul 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9585874

    Nuclear transport modulators and uses thereof

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9550757

    Nuclear transport modulators and uses thereof

    Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9428490

    Nuclear transport modulators and uses thereof

    Expires Mon Aug 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9303000

    Olefin containing nuclear transport modulators and uses thereof

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9266843

    Nuclear transport modulators and uses thereof

    Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9206158

    Hydrazide containing nuclear transport modulators and uses thereof

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9096543

    Nuclear transport modulators and uses thereof

    Expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9079865

    Hydrazide containing nuclear transport modulators and uses thereof

    Expires Mon Jul 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8999996

    Hydrazide containing nuclear transport modulators and uses thereof

    Expires Mon Apr 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8513230

    Nuclear transport modulators and uses thereof

    Expires Mon Aug 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Karyopharm Therapeutics have?

38 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Karyopharm Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.